Overview

Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

Status:
Recruiting
Trial end date:
2024-03-18
Target enrollment:
Participant gender:
Summary
This is Phase II / III, Prospective, single arm, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed / Refractory B-Acute Lymphoblastic Leukaemia
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
National University of Malaysia
Collaborators:
Gaia Science
GAIA Sdn Bhd
Treatments:
Cyclophosphamide
Fludarabine
Fludarabine phosphate